Abstract:HZ-H08905 is a first-class and potent CK1ε/PI3Kδ dual inhibitor with nano-molar inhibitory potency at the enzyme and cellular level. In vivo tumor growth inhibition is also observed in multiple B-cell lymphoma xenograft mouse model including OCI-LY10 and SU-DHL-6. HZ-H08905 has unique structure and activity profile distinct from other PI3Kδ inhibitors in development: 1) dual inhibition of CK1ε and PI3Kδ may exert synergistic effects through inhibiting both CK1ε/Wnt signaling and PI3K signaling in malignant lymphocytes, 2) dual inhibition of CK1ε and PI3Kδ also enhance anti-tumor immunity through regulation of tumor microenvironment; 3) preclinical studies also suggested an improved therapeutic window with a differentiated safety profile. HZ-H08905-101 is an ongoing Phase 1, first-in-human, open-label, multicenter, multiple-dose ascending and expansion study of oral HZ-H08905 monotherapy in patients with relapsed/ refractory advanced hematologic malignancies in China (CTR20213233). The aim of this study was to investigate the safety, tolerability, and pharmacokinetic properties of HZ-H08905, in order to determine the maximum tolerated dose (MTD) based on dose limiting toxicity (DLT) and assess preliminary anti-tumor activity in patients with non-Hodgkin lymphoma (NHL), including B-cell lymphoma and T-cell lymphoma. The phase Ia (dose escalation) part of the study was designed to determine MTD and recommended dose for expansion (RDE) of HZ-H08905. HZ-H08905 was administered orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The dose escalation part was initiated with a dose titration in the initial cohort, followed by a 3 + 3 design. Efficacy evaluable patients included all dosed patients who underwent their first response evaluation or discontinued therapy. Response was assessed at the beginning of cycle 3 and then every 12 weeks from cycle 3 and every 24 weeks from cycle 18, and was measured according to IWWM-7 for WM, or IWCLL 2018 for CLL/SLL, or Lugano 2014 criteria for other NHL. Safety was assessed in all patients. The preliminary results showed that HZ-H08905 was well tolerated and showed clinical activity in patients with R/R NHL, especially R/R PTCL. The efficacy, safety, and tolerability of HZ-H08905 in R/R PTCL patients at recommended phase II dose (RP2D) established in the phase I dose escalation and expansion part will be investigated in phase 2.

Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma

Identification of a potent and selective phosphatidylinositol 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma

Dual CK1/PI3K Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Design, Synthesis and Structure-Activity Relationship Study of Piperazinone-Containing Thieno[3,2-d]pyrimidine Derivatives As New PI3Kδ Inhibitors.

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

TYM-3-98, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Preclinical Antitumor Activity in B-cell Lymphomas

SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.

Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors

Identification of Novel Piperazinylquinoxaline Derivatives As Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors

A Novel Dual Pi3k Alpha/Mtor Inhibitor Pi-103 with High Antitumor Activity in Non-Small Cell Lung Cancer Cells

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Identification of Novel Potential PI3Kα Inhibitors for Cancer Therapy

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma

Puquitinib Mesylate, an Inhibitor of Phosphatidylinositol 3-Kinase P110δ, for Treating Relapsed or Refractory Non-Hodgkin's Lymphoma.

Brd4 Inhibition Sensitizes Aggressive Non-Hodgkin Lymphomas To Pi3k Delta Inhibitors By Suppressing Pi3k Reactivation And C-Myc Expression

SAR Study of 5-Alkynyl Substituted Quinazolin-4(3H)-ones As Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitors.

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor

Design, Synthesis, and Biological Evaluation of Novel 3-Substituted Imidazo[1,2-A]pyridine and Quinazolin-4(3H)-one Derivatives As PI3Kα Inhibitors.